PepTalk 2017
PepTalk 2017

Pipeline Two Header


Antibody-based therapeutics comprise the bulk of approved biologics – as well as biologics that are in development. This pipeline explores the emerging field of next-generation antibody therapeutics, including Antibody-Drug Conjugates, Bispecific Antibody Therapeutics and engineering antibodies that fight cancer. The weeklong Antibody Therapeutics pipeline reveals R&D strategies, clinical results and efficacy data for these promising molecules.

Conferences Include:

January 9-10

Engineering Next-Generation Cancer Immunotherapies

January 10-11

Antibody-Drug Conjugates

January 12-13

Bispecific Antibody Therapeutics